DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Anaplastic Astrocytoma - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Anaplastic Astrocytoma Overview
- Therapeutics Development
- Pipeline Products for Anaplastic Astrocytoma - Overview
- Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis
- Anaplastic Astrocytoma - Therapeutics under Development by Companies
- Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes
- Anaplastic Astrocytoma Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Anaplastic Astrocytoma - Products under Development by Companies
- Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes
- Anaplastic Astrocytoma - Companies Involved in Therapeutics Development
- Aduro BioTech, Inc.
- Axelar AB
- Boehringer Ingelheim GmbH
- Burzynski Research Institute, Inc.
- Cavion LLC
- Celldex Therapeutics, Inc.
- e-Therapeutics Plc
- Medicenna Therapeutics, Inc.
- Millennium Pharmaceuticals, Inc.
- Novartis AG
- Orbus Therapeutics, Inc.
- Pfizer Inc.
- Tocagen Inc.
- TVAX Biomedical, Inc.
For more information visit http://www.researchandmarkets.com/research/h3r58z/anaplastic